Interviews and Presentations
HAYWARD (KPIX 5) - We've combined smart drug delivery where we've timed the delivery of the nicotine to deal with the patients or the consumers cravings," Chrono Therapeutics, R&D Co-VP, Dr. Patrick Ruane said.
Alan Levy, PhD Chairman and Chief Executive Officer of Chrono Therapeutics, talks about Chrono Therapeutics and what makes the company and its platform worthy of the World Economic Forum's 2016 Technology Pioneer award.
Jenny Hapgood, Vice President of Marketing & Product Management at Chrono Therapeutics, discusses the future of personalized medicine and its application to smoking cessation at SXSW 2016.
Alan Levy, PhD Chairman and Chief Executive Officer of Chrono Therapeutics, talks about personalized drug delivery with Tim Reha of Digital Health LIVE.
Dr. Patrick Ruane, SVP of Research & Development, presented Chrono's clinical trial data at the SRNT Annual Conference 2016.
Chrono Therapeutics was featured in The MedTech Strategist, March 16, 2016, Vol. 3, No. 4.
In the News
Forbes, September 8, 2016
Biotech hasn’t come up with many innovative answers in the past two decades to one of the world’s toughest public health problems — smoking. Now a startup in the San Francisco Bay area is raising a bundle of cash to help smokers kick the habit with some carefully calibrated drug delivery and behavioral nudges.
Hayward, Calif.-based Chrono Therapeutics is announcing today it has raised $47.6 million in a Series B round of venture capital. The investment was led by Kaiser Permanente Ventures ...
The Wall Street Journal, Jun 26, 2016
From growing blood vessels in labs to applying advanced nanotechnology to cancer testing, here are some emerging technologies that could have a big impact on medicine in coming years.
Cigarette smoking causes one-fifth of U.S. deaths each year, but the most commonly used methods for quitting have spotty effectiveness. Harvard University researchers found in a 2012 study that nicotine gum and patches were no better than going cold turkey in helping smokers quit long term.
Drug Store News, April 14, 2016
Unit shipments for wearable devices were expected to drive about $32 billion in revenue by 2019 — more than three times the $10 billion in revenue the market saw in 2013, according to a 2015 IHS Technology white paper on the wearables market. Beside the business applications IHS identified, it also focused on consumer possibilities in the wearables market — as fitness trackers, health data collectors and beyond.
The potential that IHS identified is something that entrepreneurs are currently working on tapping into, and industry observers have taken note of the evolving role of wearables.
Pharm Pro, March 4, 2016
Chrono Therapeutics announced that clinical data for the company's smoking cessation technology showed a statistically significant reduction in nicotine cravings in a trial of adult male smokers. The data were presented at the Society of Research on Nicotine & Tobacco's 22nd Annual Meeting.
Chrono's wearable transdermal drug delivery device times nicotine delivery to when smokers have their strongest cravings. For example, 75 percent of all smokers reach for their first cigarette within 30 minutes of waking up.
Medical Device and Diagnostic Industry, January 14, 2016
The skin patch is an established and proven tool in nicotine replacement therapy, but it still has limitations. Strongest right after it is first applied to the skin, a nicotine patch's waning potency later in the day can lead smokers to relapse.
Hayward, CA-based Chrono Therapeutics is using medical technology to modernize traditional approaches to smoking cessation. The company has developed a way to provide timed transdermal drug delivery via a wearable device.
MedCity News, March 3, 2015
Rock Health entered the arena of digital health tools for smoking cessation with an investment in Chrono Therapeutics, according to a company statement. The pharmaceutical company produces a wearable drug delivery tool and companion app called SmartStop, which functions as a digital health coach to help smokers quit. The investment follows a $32 million Series A round in June.
WIRED, January 28, 2015
Yes, we already have the nicotine patch and nicotine gum and all sorts of anti-smoking lozenges. But Levy believes we can turn quitting into a more exact science with a wearable device that careful administers nicotine to your particular specifications. ...
Brit + Co, December 13, 2014
When someone says "wearables" you naturally think about fitness and health wearables or smart watches. These wearables can relay notifications to you or track your calories burned -- which is cool and all -- but the medical industry has been making their own amazing advancements in ...
Medical Device and Diagnostic Industry, August 12, 2014
The true value of wearable technologies lies in the regulated medical world where it can affect large-scale change, writes Wende Hutton, a West Coase venture capitalist. Thanks Google! With the recent press on Google's new frontier of the human body called the Baseline ...
FOX Business, June 12, 2014
Like the Fitbit or the Jawbone Up, the newest piece of wearable technology aims to make users healthier. But instead of counting steps, Chrono Therapeutics' SmartStop wearable is intended to help smokers leave cigarettes behind. The SmartStop device can be worn as a watch, an ...
Silicon Valley Business Journal, June 12, 2014
Canaan general partner Wende Hutton, 5AM's Jim Young and Fountain's Aidan King will join Chrono's board as part of the financing, according to a news release. The capital will allow Chrono Therapeutics to complete development and clinical studies of it's SmartStop device ...
TechCrunch, June 12, 2014
Although the company is launching with a device to treat addiction to smoking, Dr. Levy sees applications that range far beyond kicking the nicotine habit. He says that the company's technology can be used to treat other diseases from addiction to prescription ...
February 1, 2018
Chrono Therapeutics, a pioneer in digital drug therapy, today announced that Alan Levy Ph.D., Chief Executive Officer (CEO) and Chairman of the Board of Directors is retiring. David A. Happel has been appointed as the new CEO and current Board member James Young will assume the role of Chairman of the Board. Dr. Levy will continue to serve as a member of the Board.
September 8, 2016
Chrono Therapeutics, a pioneer in digital drug therapy and recent recipient of the World Economic Forum Technology Pioneer Award, today announced that it has closed a $47.6 million Series B financing. The round was led by Kaiser Permanente Ventures and included investments by Endeavour Vision, Xeraya Capital Labuan Ltd, Asahi Kasei, Emergent Medical Partners, Hikma Ventures, Cota Capital, and Mission Bay Capital.
July 20, 2016
Chrono Therapeutics, a pioneer in digital drug therapy, announced today that its Hayward, California location has received ISO 13485 certification from accredited certification body DEKRA Certification B.V. This certification demonstrates Chrono’s commitment to establishing and following policies, practices and procedures to meet the customer, safety and regulatory requirements applicable to medical devices.
March 4, 2016
Chrono Therapeutics, a pioneer in digital drug therapy, today announced that clinical data for the company's smoking cessation technology showed a statistically significant reduction in nicotine cravings in a trial of adult male smokers. The data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.
August 25, 2015
Chrono Therapeutics, a pioneer in digital drug therapy, today announced it has received a second Phase 1 and Phase 2 Fast Track Small Business Innovation Research (SBIR) grant award from the National Cancer Institute (NCI). This award of up to $2.3 million will support final product development of the digital portion of Chrono's patient-individualized smoking cessation therapy as well as pilot efficacy trials of the system.
March 3, 2015
Chrono Therapeutics, a pioneer in digital drug products, today announced an investment by Rock Health, the leading seed fund in digital health, to support the advancement of Chrono’s SmartStop™ programmable transdermal drug delivery system and real-time behavioral support program for smoking cessation.
June 12, 2014
Chrono Therapeutics, a pioneer in digital drug products, announced today the close of a $32 million Series A financing round, led by Canaan Partners and 5AM Ventures. Additional participants in the financing were Fountain Healthcare Partners, Mayo Clinic and GE Ventures.
February 10, 2014
The National Cancer Institute division of the NIH has recently awarded Chrono Therapeutics (CHRONO), a pioneer in digital drug products, a $2.23M grant to commercialize its lead product-SmartStop.™ Smartstop is the first “smart” transdermal nicotine replacement therapy (NRT) system that synchronizes the delivery of nicotine at the times of cravings to prevent cravings from occurring.